{"entity":{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","aka":[],"tldr":"Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.","summary":"Summit Therapeutics, based in Miami and listed as SMMT, holds the Western rights to ivonescimab, Akeso's PD-1 by VEGF bispecific antibody, and is running the global HARMONi trials. HARMONi-3 tests it in first-line non-small-cell lung cancer and HARMONi-7 in PD-L1-high disease, both phase 3, and the company's biologics licence strategy follows the overall survival result of the HARMONi trial. OnCo links it to non-small-cell lung cancer and cutaneous squamous cell carcinoma, to HARMONi-A, and to the HARMONi-2 paper in which ivonescimab beat pembrolizumab head to head. Whether a Chinese head-to-head win can be reproduced in a Western population, and whether the FDA will accept it, is the open question the company exists to answer. Ivonescimab has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.smmttx.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07228832","nct06396065","nct06767514","nct07815665"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Miami, FL","country":"US","companyType":"biotech","website":"https://www.smmttx.com","ticker":"SMMT","investors":[],"funding":[]},"route":"/companies/summit-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"trial":[{"id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","route":"/trials/nct07535437/"},{"id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/"},{"id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","route":"/trials/nct07535463/"},{"id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/"},{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/"},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/"},{"id":"nct07405190","kind":"trial","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","route":"/trials/nct07405190/"},{"id":"nct06959550","kind":"trial","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","route":"/trials/nct06959550/"},{"id":"nct07057791","kind":"trial","name":"Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07057791/"},{"id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","route":"/trials/nct07234877/"},{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","route":"/trials/nct06396065/"},{"id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07228832/"},{"id":"nct07359456","kind":"trial","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","route":"/trials/nct07359456/"}],"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"paper":[{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/"}]}}